← Product Code [MKJ](/submissions/CV/subpart-f%E2%80%94cardiovascular-therapeutic-devices/MKJ) · K062970 # I-PAD (K062970) _Cu Medical Systems, Inc. · MKJ · Jan 22, 2008 · Cardiovascular · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/CV/subpart-f%E2%80%94cardiovascular-therapeutic-devices/MKJ/K062970 ## Device Facts - **Applicant:** Cu Medical Systems, Inc. - **Product Code:** [MKJ](/submissions/CV/subpart-f%E2%80%94cardiovascular-therapeutic-devices/MKJ.md) - **Decision Date:** Jan 22, 2008 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 870.5310 - **Device Class:** Class 3 - **Review Panel:** Cardiovascular - **Attributes:** Therapeutic, Pediatric ## Indications for Use The i-PAD NF1200 is used to treat a person suffering from sudden cardiac arrest (SCA) and who exhibits symptoms of - No movement and no response when shaken . - No normal breathing . ## Device Story i-PAD NF1200 is a semi-automated external defibrillator (AED) for use by trained responders. Device continuously acquires patient ECG and performs arrhythmia detection, excluding periods of CPR. Operation follows AHA 2005 guidelines. Upon detecting shockable rhythm, device prompts user to press SHOCK button. Delivers 150-Joule biphasic truncated exponential shock; adjusts timing based on patient impedance. If shock not delivered, device internally discharges. Features include voice prompts, data storage/transmission, and periodic self-tests (daily, weekly, 28-day, power-on). Lightweight, battery-powered for portability. Healthcare providers use audio/visual indicators to monitor status and guide rescue. Benefits include rapid defibrillation for SCA patients. ## Clinical Evidence Bench testing only. Shock waveform effectiveness and safety validated via oscilloscope measurements comparing energy parameters to predicate devices. Arrhythmia detection algorithm performance validated against AHA and ANSI/AAMI DF80 standards. Electrical safety verified per EN60601-1 and EN60601-2-4. ## Technological Characteristics Biphasic truncated exponential waveform; 150-Joule output; impedance-compensated timing. Battery-powered. Periodic self-test functionality (daily, weekly, 28-day). Compliant with EN60601-1, EN60601-2-4, and ANSI/AAMI DF80 standards. Data storage and transmission capability. ## Regulatory Identification An automated external defibrillator (AED) system consists of an AED and those accessories necessary for the AED to detect and interpret an electrocardiogram and deliver an electrical shock (e.g., battery, pad electrode, adapter, and hardware key for pediatric use). An AED system analyzes the patient's electrocardiogram, interprets the cardiac rhythm, and automatically delivers an electrical shock (fully automated AED), or advises the user to deliver the shock (semi-automated or shock advisory AED) to treat ventricular fibrillation or pulseless ventricular tachycardia. ## Predicate Devices - Philips HeartStart OnSite ([K020715](/device/K020715.md)) - Philips HeartStart FR2+ ([K013425](/device/K013425.md)) - Defibtech Sentry DDU-100A ([K013896](/device/K013896.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ JAN 222 2008 167970 # 510(k) Summary ## Submitted on behalf of: Company Name: CU Medical Systems, Inc Address: Medical Industry Complex, Bldg. No. 2, 1720-26 Taejang-dong, Wonju-si, Gangwon-do, 220-120 Republic of Korea Telephone: 8233 747 7657 8233 747 7659 Fax: by: Telephone: Fax: CONTACT PERSON: DATE PREPARED: Elaine Duncan January 15, 2008 Stillwater, MN 55082 PO Box 560 715-549-6035 715-549-5380 Elaine Duncan, MS.ME., RAC President, Paladin Medical, Inc. DEVICE TRADE NAME: i-PAD NF1200 Semi-automated External Defibrillator COMMON NAME: Semi-automated External Defibrillator CLASSIFICATION NAMES: Low Energy Defibrillator PRODUCT CODE and REGULATION NUMBER: MKJ, 21 CFR 870.5310 -Automated External Defibrillator #### PREDICATE DEVICES: The i-PAD NF1200 is substantially equivalent to other marketed AEDs in the United States, specifically the following: | Device Name | Manufacturer | 510(K) Number | |---------------------------|-------------------------|---------------| | Philips HeartStart OnSite | Philips Medical Systems | K020715 | | Philips HeartStart FR2+ | Philips Medical Systems | K013425 | | Defibtech Sentry DDU-100A | Defibtech, LLC | K013896 | The shock delivered by the device is in the form of a Biphasic Truncated Exponential which has characteristics and results that are substantially equivalent to the cited predicate devices (K013425 and K013896). The operation of this device and its minor differences with the predicate device does not raise new issues regarding safety and efficacy. {1}------------------------------------------------ # DESCRIPTION of the DEVICE: The i-PAD NF1200 is a semi-automated external defibrillator designed for minimally trained individuals. It provides simple and direct voice prompts and indications for a straightforward rescue operation. The i-PAD NF1200 needs the user to press its SHOCK button to deliver a defibrillating shock. During a resoue operation, it continuously acquires the electrocardiogram (ECG) of the patient. It also conducts arrhythmia detection continuously except during cardiopulmonary resuscitation (CPR). The timing and duration of the CPR are in accordance with the recommendations of the American Heart Association (AHA) 2005 Guidelines for CPR and Emergency Cardiovascular Care (ECC). The i-PAD NF1200 is lightweight and battery powered for maximum portability. Its battery pack has a capacity of 200 shocks (10 hours of operating time.) It delivers a 150-Joule biphasic truncated exponential shock waveform that it compensates for patient impedance by adjusting its timing parameter. If the user decides not to deliver a charge, the i-PAD NF1200 disarms itself by dumping the charge into an internal resistive load. The i-PAD NF1200 is capable of saving data and transmitting them to an external device. The i-PAD NF1200 conducts periodic (daily, weekly, and 28-day) self-tests, a battery insertion self-test, and self-tests during power-ON and run-time. It informs the user if an error is detected through audio and visual indicators. #### Indications for Use The i-PAD NF1200 is used to treat a person suffering from sudden cardiac arrest (SCA) and who exhibits symptoms of - No movement and no response when shaken . - No normal breathing . #### Contraindication for Use The device must not be used on a person who: - Is moving or is responsive when shaken . - . Is breathing normally - Target Patients - . Adults - Children over 55 lbs or 8 years old . - The device is not to be used on children below 8 years old or under 55 lbs . #### Intended User The device is intended for use by persons: - who have been specifically trained in its operation. . - who have training in cardiopulmonary resuscitation (CPR) or other physician-authorized . emergency medical response program in accordance with local and state requirements {2}------------------------------------------------ ### COMPARISON OF TECHNOLOGY CHARACTERISTICS The i-PAD NF1200 employs the same fundamental technological characteristics as the predicate devices. Differences in implementation are verified and validated using relevant test protocols. #### SUMMARY of TESTING: #### Shock Waveform Effectiveness and Safety Substantial equivalence with the predicate device is shown by bench testing. The submission device and the predicate device are discharged and the shock waveform parameters are captured using an oscilloscope with energy measurement capability. Statistical analysis is used to show that the mean values of the shock waveform parameters of the i-PAD NF1200 are closer to the mean values of the shock waveform parameters of the Philips HeartStart FR2+ than the mean values of the Defibtech DDU-100A shock waveform parameters. #### Arrhythmia Detection Algorithm The arrhythmia detection algorithm is tested using the recommendations of the American Heart Association and the ANSI/AAMI DF80 Standard. #### Electrical Safety and Compliance to Defibrillator Standard The i-PAD NF1200 was tested using EN60601-1 and EN60601-2-4. The EN60601-2-4 has the same contents as the ANSI/AAMI DF80 Standard except for some additional sections in the ANSI/AAMI DF80 regarding Defibrillator Electrodes and External Pacing. #### CONCLUSION The i-PAD NF1200 is substantially equivalent to its predicate devices. Testing shows that the submission device does not raise new issues of safety and effectiveness. {3}------------------------------------------------ Public Health Service Image /page/3/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized caduceus symbol, which features a staff with a serpent entwined around it, and three horizontal lines above it. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the symbol. JAN 22 2008 Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 CU Medical Systems, Inc c/o Ms. Elaine Duncan, M.S.M.E., RAC President, Paladin Medical, Inc. PO Box 560 Stillwater, MN 55082 Re: K062970 Trade/Device Name: I-Pad NF1200 Semi-Automated External Defibrillator Regulation Number: 21 CFR 870.5310 Regulation Name: Automated external defibrillator Regulatory Class: Class III Product Code: MKJ Dated: November 28, 2007 Received: November 29, 2007 Dear Ms Duncan: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {4}------------------------------------------------ # Page 2 - Ms. Elaine Duncan, M.S.M.E., RAC Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html. Sincerely yours, Bram D. Zuckerman, M.D. Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {5}------------------------------------------------ # Indications for Use 510(k) Number (if known): Device Name: i-PAD NF1200 Indications For Use: The i-PAD NF1200 is used to treat a person suffering from sudden cardiac arrest (SCA) and who exhibits symptoms of - No movement and no response when shaken . - No normal breathing . | Prescription Use | X | |-----------------------------|---| | (Part 21 CFR 801 Subpart D) | | AND/OR | Over-The-Counter Use | | |------------------------|--| | (21 CFR 801 Subpart C) | | (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE)*(Division Sign/Off)* Division of Cardiovascular Devices 510(k) number K062970 Page 1 of --- **Source:** [https://fda.innolitics.com/submissions/CV/subpart-f%E2%80%94cardiovascular-therapeutic-devices/MKJ/K062970](https://fda.innolitics.com/submissions/CV/subpart-f%E2%80%94cardiovascular-therapeutic-devices/MKJ/K062970) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com